DiaMedica Historical Balance Sheet

DMAC Stock

USD 4.70 0.52 12.44%

Trend analysis of DiaMedica Therapeutics balance sheet accounts such as Other Current Liabilities of 1.8 M or Total Current Liabilities of 2.9 M provides information on DiaMedica Therapeutics' total assets, liabilities, and equity, which is the actual value of DiaMedica Therapeutics to its prevalent stockholders. By breaking down trends over time using DiaMedica Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining DiaMedica Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether DiaMedica Therapeutics is a good buy for the upcoming year.

DiaMedica Therapeutics Inventory

136,448

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

About DiaMedica Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of DiaMedica Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. DiaMedica Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of DiaMedica Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which DiaMedica currently owns. An asset can also be divided into two categories, current and non-current.

DiaMedica Therapeutics Balance Sheet Chart

At present, DiaMedica Therapeutics' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 2.9 M, whereas Short and Long Term Debt Total is forecasted to decline to about 276 K.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Net Debt Total Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of DiaMedica Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in DiaMedica Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on DiaMedica Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of DiaMedica Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most accounts from DiaMedica Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into DiaMedica Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.At present, DiaMedica Therapeutics' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 2.9 M, whereas Short and Long Term Debt Total is forecasted to decline to about 276 K.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	52K	469K	400K	276.0K
Total Assets	45.6M	34.4M	54.2M	56.9M

Short Long Term Debt Total Total Assets

DiaMedica Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Other Current Assets	Net Tangible Assets	Property Plant Equipment	Capital Surpluse	Current Deferred Revenue	Non Current Liabilities Total
Total Assets		-0.27	0.79	0.78	1.0	0.83	-0.36	-0.92	0.18	0.34	-0.06	-0.38	1.0	0.34	0.96	0.97	0.78	0.88	1.0	0.19	0.83	0.99	0.83	0.92	0.24	-0.22
Short Long Term Debt Total	-0.27		-0.06	0.0	-0.28	-0.1	0.46	0.19	0.19	-0.46	0.4	0.34	-0.28	-0.51	-0.23	-0.22	0.04	-0.12	-0.29	-0.09	-0.21	-0.29	-0.06	-0.48	0.15	0.86
Other Current Liab	0.79	-0.06		0.86	0.78	0.83	-0.26	-0.81	0.1	0.24	-0.14	-0.08	0.79	0.41	0.83	0.88	0.85	0.85	0.79	-0.11	0.74	0.78	0.85	0.76	0.41	0.03
Total Current Liabilities	0.78	0.0	0.86		0.76	0.8	-0.16	-0.79	0.54	0.14	-0.3	-0.03	0.79	0.23	0.81	0.84	0.99	0.82	0.79	0.11	0.71	0.78	0.81	0.72	0.39	0.11
Total Stockholder Equity	1.0	-0.28	0.78	0.76		0.82	-0.37	-0.92	0.16	0.35	-0.05	-0.39	1.0	0.34	0.96	0.97	0.77	0.87	1.0	0.19	0.83	0.99	0.83	0.92	0.23	-0.24
Property Plant And Equipment Net	0.83	-0.1	0.83	0.8	0.82		-0.22	-0.89	0.15	0.21	-0.09	0.04	0.83	0.35	0.93	0.88	0.85	0.99	0.83	0.25	0.75	0.87	0.98	0.83	0.21	0.02
Net Debt	-0.36	0.46	-0.26	-0.16	-0.37	-0.22		0.28	0.04	-1.0	0.02	0.06	-0.35	-0.72	-0.25	-0.35	-0.13	-0.21	-0.36	0.26	-0.58	-0.36	-0.17	-0.48	-0.15	0.47
Retained Earnings	-0.92	0.19	-0.81	-0.79	-0.92	-0.89	0.28		-0.18	-0.27	0.2	0.25	-0.93	-0.34	-0.97	-0.95	-0.82	-0.92	-0.93	-0.22	-0.78	-0.93	-0.88	-0.9	-0.1	0.24
Accounts Payable	0.18	0.19	0.1	0.54	0.16	0.15	0.04	-0.18		-0.03	-0.24	0.06	0.19	-0.22	0.16	0.2	0.51	0.15	0.19	0.12	0.13	0.19	0.11	0.14	0.26	0.26
Cash	0.34	-0.46	0.24	0.14	0.35	0.21	-1.0	-0.27	-0.03		-0.03	-0.06	0.33	0.71	0.24	0.33	0.12	0.19	0.34	-0.22	0.56	0.35	0.15	0.47	0.14	-0.46
Non Current Assets Total	-0.06	0.4	-0.14	-0.3	-0.05	-0.09	0.02	0.2	-0.24	-0.03		0.21	-0.11	-0.15	-0.14	-0.08	-0.29	-0.09	-0.11	-0.39	-0.07	-0.13	-0.06	-0.2	0.16	0.34
Non Currrent Assets Other	-0.38	0.34	-0.08	-0.03	-0.39	0.04	0.06	0.25	0.06	-0.06	0.21		-0.39	0.07	-0.24	-0.3	0.0	-0.03	-0.39	-0.06	-0.11	-0.38	0.04	-0.31	-0.06	0.36
Cash And Short Term Investments	1.0	-0.28	0.79	0.79	1.0	0.83	-0.35	-0.93	0.19	0.33	-0.11	-0.39		0.33	0.96	0.97	0.79	0.88	1.0	0.21	0.83	0.99	0.83	0.92	0.23	-0.23
Net Receivables	0.34	-0.51	0.41	0.23	0.34	0.35	-0.72	-0.34	-0.22	0.71	-0.15	0.07	0.33		0.35	0.38	0.23	0.34	0.34	-0.13	0.46	0.32	0.33	0.54	0.17	-0.48
Common Stock Shares Outstanding	0.96	-0.23	0.83	0.81	0.96	0.93	-0.25	-0.97	0.16	0.24	-0.14	-0.24	0.96	0.35		0.97	0.84	0.96	0.96	0.25	0.8	0.97	0.93	0.93	0.2	-0.18
Other Stockholder Equity	0.97	-0.22	0.88	0.84	0.97	0.88	-0.35	-0.95	0.2	0.33	-0.08	-0.3	0.97	0.38	0.97		0.84	0.91	0.97	0.06	0.82	0.97	0.87	0.94	0.32	-0.19
Total Liab	0.78	0.04	0.85	0.99	0.77	0.85	-0.13	-0.82	0.51	0.12	-0.29	0.0	0.79	0.23	0.84	0.84		0.87	0.79	0.21	0.72	0.79	0.86	0.73	0.38	0.15
Property Plant And Equipment Gross	0.88	-0.12	0.85	0.82	0.87	0.99	-0.21	-0.92	0.15	0.19	-0.09	-0.03	0.88	0.34	0.96	0.91	0.87		0.88	0.25	0.79	0.91	0.99	0.85	0.22	-0.01
Total Current Assets	1.0	-0.29	0.79	0.79	1.0	0.83	-0.36	-0.93	0.19	0.34	-0.11	-0.39	1.0	0.34	0.96	0.97	0.79	0.88		0.21	0.83	0.99	0.83	0.92	0.23	-0.24
Short Term Debt	0.19	-0.09	-0.11	0.11	0.19	0.25	0.26	-0.22	0.12	-0.22	-0.39	-0.06	0.21	-0.13	0.25	0.06	0.21	0.25	0.21		0.02	0.24	0.23	0.16	-0.35	0.02
Other Current Assets	0.83	-0.21	0.74	0.71	0.83	0.75	-0.58	-0.78	0.13	0.56	-0.07	-0.11	0.83	0.46	0.8	0.82	0.72	0.79	0.83	0.02		0.82	0.8	0.75	0.19	-0.18
Net Tangible Assets	0.99	-0.29	0.78	0.78	0.99	0.87	-0.36	-0.93	0.19	0.35	-0.13	-0.38	0.99	0.32	0.97	0.97	0.79	0.91	0.99	0.24	0.82		0.86	0.93	0.22	-0.21
Property Plant Equipment	0.83	-0.06	0.85	0.81	0.83	0.98	-0.17	-0.88	0.11	0.15	-0.06	0.04	0.83	0.33	0.93	0.87	0.86	0.99	0.83	0.23	0.8	0.86		0.79	0.2	0.04
Capital Surpluse	0.92	-0.48	0.76	0.72	0.92	0.83	-0.48	-0.9	0.14	0.47	-0.2	-0.31	0.92	0.54	0.93	0.94	0.73	0.85	0.92	0.16	0.75	0.93	0.79		0.28	-0.41
Current Deferred Revenue	0.24	0.15	0.41	0.39	0.23	0.21	-0.15	-0.1	0.26	0.14	0.16	-0.06	0.23	0.17	0.2	0.32	0.38	0.22	0.23	-0.35	0.19	0.22	0.2	0.28		0.35
Non Current Liabilities Total	-0.22	0.86	0.03	0.11	-0.24	0.02	0.47	0.24	0.26	-0.46	0.34	0.36	-0.23	-0.48	-0.18	-0.19	0.15	-0.01	-0.24	0.02	-0.18	-0.21	0.04	-0.41	0.35

Click cells to compare fundamentals

DiaMedica Therapeutics Account Relationship Matchups

DiaMedica Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.1M	28.1M	45.6M	34.4M	54.2M	56.9M
Short Long Term Debt Total	178K	118K	52K	469K	400K	276.0K
Other Current Liab	1.1M	791K	917K	1.3M	1.7M	1.8M
Total Current Liabilities	1.3M	2.0M	1.5M	2.2M	2.8M	2.9M
Total Stockholder Equity	7.6M	26.0M	44.0M	31.8M	51.1M	53.6M
Property Plant And Equipment Net	217K	174K	112K	560K	485K	509.3K
Net Debt	(3.7M)	(7.3M)	(4.7M)	(4.3M)	(4.1M)	(4.4M)
Retained Earnings	(56.6M)	(68.9M)	(82.5M)	(96.2M)	(115.6M)	(109.8M)
Accounts Payable	182K	1.1M	509K	734K	926K	563.1K
Cash	3.9M	7.4M	4.7M	4.7M	4.5M	3.5M
Non Current Assets Total	217K	174K	112K	560K	485K	638.8K
Non Currrent Assets Other	217K	100K	(40.4M)	(1.0)	(0.9)	(0.94)
Cash And Short Term Investments	7.9M	27.5M	45.1M	33.5M	52.9M	55.5M
Net Receivables	823K	340K	130K	82K	369K	387.5K
Common Stock Shares Outstanding	12.0M	15.7M	20.8M	26.4M	32.6M	34.2M
Liabilities And Stockholders Equity	9.1M	28.1M	45.6M	34.4M	54.2M	56.9M
Other Stockholder Equity	64.2M	94.9M	126.6M	128.1M	166.6M	174.9M
Total Liab	1.4M	2.1M	1.5M	2.6M	3.1M	3.3M
Property Plant And Equipment Gross	217K	174K	179K	560K	585K	614.3K
Total Current Assets	8.8M	27.9M	45.4M	33.8M	53.7M	56.4M
Accumulated Other Comprehensive Income	2K	(2K)	(51K)	(74K)	6K	5.7K
Short Term Debt	60K	130K	98K	138K	166K	90.0K
Other Current Assets	47K	74K	197K	251K	411K	431.6K
Net Tangible Assets	17.0M	7.6M	26.0M	44.0M	50.6M	53.2M
Short Term Investments	4.0M	20.1M	40.4M	28.8M	48.4M	50.8M
Property Plant Equipment	217K	74K	112K	560K	644K	676.2K
Capital Surpluse	41.0M	63.0M	64.2M	94.9M	109.2M	114.6M
Non Current Liabilities Total	118K	53K	3K	400K	317K	158.5K
Capital Lease Obligations	178K	118K	52K	469K	400K	420K
Net Invested Capital	7.6M	26.0M	44.0M	31.8M	51.1M	28.0M
Net Working Capital	7.5M	25.9M	43.9M	31.7M	50.9M	27.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:

How To Invest In DiaMedica

Details

Is DiaMedica Stock a good investment?

Details

What is DiaMedica Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.56)

Return On Assets

(0.24)

Return On Equity

(0.35)

The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

DiaMedica Historical Balance Sheet

DiaMedica Therapeutics Inventory

136,448

About DiaMedica Balance Sheet Analysis

DiaMedica Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Net Debt

Total Liab

DiaMedica Therapeutics balance sheet Correlations

DiaMedica Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

DiaMedica Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Net Tangible Assets	- 0.93	Retained Earnings
Total Current Assets	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.93	Retained Earnings